All In Biotech

NDA 021991 · Msd Sub Merck

Zolinza

Vorinostat · Oral · Histone Deacetylase Inhibitor

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 11, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Oct 6, 2006

Approved uses

2

Original approval plus efficacy supplements

Registered trials

278

9 Phase 3, 10 recruiting

FAERS reports

2,165

1,872 serious, 423 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 12, 2024.

ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. ( 1 )

Mechanism: Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC 50 <86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of proteins, including histones and transcription factors. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. Hypoacetylation of histones is associated with a condensed chromatin structure and repression of gene...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 23, 2009 Supplement 4 · Efficacy LetterLabel
  • Oct 6, 2006 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
  • ZOLINZA · VORINOSTAT 100MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vorinostat" as an intervention, any sponsor and status, largest first.

All 278 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia239
  • thrombocytopenia153
  • anaemia135
  • product use in unapproved indication133
  • diarrhoea130
  • nausea128
  • fatigue126
  • off label use115
  • vomiting113
  • sepsis111
  • platelet count decreased106
  • dehydration102

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20063
200743
200852
200954
201082
201156
2012190
2013263
2014284
2015291
2016106
201791
201896
201946
2020110
202188
2022141
202354
202450
202536
202629

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zolinza (Vorinostat)

2024 spending

$3.7M

Beneficiaries

75

387 claims

Per beneficiary

$49,294

$119.78 per unit

View as table
YearSpending
2020$3,137,397
2021$3,249,001
2022$3,907,317
2023$3,402,208
2024$3,697,070

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 223 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.